CD20

30개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved30 programs
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 1

CD20 CAR-T (CD20 CAR-T)

Relapsed and Refractory B Cell Lymphoma; Non-Hodgkin Lymphoma · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD20-CD19 cCAR T cells (CD20-CD19 cCAR T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

CD20-directed CAR-T cells with CliniMACS Prodigy® system (CD20-directed CAR-T cells with CliniMACS Prodigy® system)

B Cell Lymphoma · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleHe HuangPhase 1

CD20/CD22 dual Targeted CAR T-cells (CD20/CD22 dual Targeted CAR T-cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Friendship HospitalPhase 1

CD207 CAR-T cells (CD207 CAR-T cells)

Langerhans Cell Histiocytosis · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20 (Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20)

CD19 Negative B-cell Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 2

Mixed CD19/CD20 CAR-T Transfer (Mixed CD19/CD20 CAR-T Transfer)

Recurrent or Refractory B Cell Malignancy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
ADCLimited DatastaleOxford BioTherapeutics LtdPhase 1

OBT076, a CD205-directed antibody-drug conjugate (OBT076, a CD205-directed antibody-drug conjugate)

Solid Tumor · CD20

#CD20#ADC#Phase1#antibody-drug-conjugate#SolidTumor+1
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells (Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →